Clinical Trial Update: Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of sintilimab, bevacizumab, and temozolomide for recurrent glioblastoma; status details are not yet reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sintilimab (sintilimab)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Zhujiang Hospital | Conditions: Recurrent Glioblastoma | Phase 2 | Status: UNKNOWN